ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2022
Full spectrum flow cytometry and mass cytometry: A 32-marker panel comparison.
Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Insights into Microbiota-Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons.Vaccines · 2026Review
- Decreased PD-1Scandinavian journal of immunology · 2026Article
- Understanding nerve-tumor interactions: From basic biology to therapeutic innovation.Genes & diseases · 2026Review
- Genetically Encoded Fluorescence Barcodes Allow for Single-Cell Analysis via Spectral Flow Cytometry.ACS synthetic biology · 2025Article
- Immunological biomarkers of aging.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- Exploring the role of T cells in Alzheimer's and other neurodegenerative diseases: Emerging therapeutic insights from the T Cells in the Brain symposium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.Human vaccines & immunotherapeutics · 2024Review
- Increasing Signal Intensity of Fluorescent Oligo-Labeled Antibodies to Enable Combination Multiplexing.Bioconjugate chemistry · 2024Article
- Medicinal plant extracts interfere in gastric cancer stem cells fluorescence-based assays.Saudi journal of biological sciences · 2024Article
- Increasing Signal Intensity of Fluorescent Oligo-Labeled Antibodies to Enable Combination Multiplexing.bioRxiv : the preprint server for biology · 2024Article
- Altered immune cell phenotypes within chronically ischemic human kidneys distal to occlusive renal artery disease.American journal of physiology. Renal physiology · 2024Article
- Targeting T regulatory (TCancer drug resistance (Alhambra, Calif.) · 2024Review
- Beyond 40 fluorescent probes for deep phenotyping of blood mononuclear cells, using spectral technology.Frontiers in immunology · 2024Article
- Recent Developments in Blood Biomarkers in Neuro-oncology.Current neurology and neuroscience reports · 2023Review
- A cell-level discriminative neural network model for diagnosis of blood cancers.Bioinformatics (Oxford, England) · 2023Article
- Proteomics to study cancer immunity and improve treatment.Seminars in immunopathology · 2023Review
- tidytof: a user-friendly framework for scalable and reproducible high-dimensional cytometry data analysis.Bioinformatics advances · 2023Article
- Automated EuroFlow approach for standardized in-depth dissection of human circulating B-cells and plasma cells.Frontiers in immunology · 2023Article
- Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma.Clinical & translational immunology · 2023Article
- Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dimensional single-cell data has become an important tool in unraveling the complexity of the immune system and its involvement in homeostasis and a large array of pathologies. As technological tools are developed, researchers are adopting them to answer increasingly complex biological questions. Up until recently, mass cytometry (MC) has been the main technology employed in cytometric assays requiring more than 29 markers. Recently, however, with the introduction of full spectrum flow cytometry (FSFC), it has become possible to break the fluorescence barrier and go beyond 29 fluorescent parameters. In this study, in collaboration with the Stanford Human Immune Monitoring Center (HIMC), we compared five patient samples using an established immune panel developed by the HIMC using their MC platform. Using split samples and the same antibody panel, we were able to demonstrate highly comparable results between the two technologies using multiple data analysis approaches. We report here a direct comparison of two technology platforms (MC and FSFC) using a 32-marker flow cytometric immune monitoring panel that can identify all the previously described and anticipated immune subpopulations defined by this panel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.